Icon Plc (ICLR) Lowered to “Hold” at ValuEngine

Icon Plc (ICLR) Lowered to “Hold” at ValuEngine

ValuEngine cut shares of Icon Plc (NASDAQ:ICLR) from a buy rating to a hold rating in a research note published on Wednesday morning.

ICLR has been the topic of several other research reports. Jefferies Group LLC reissued a hold rating on shares of Icon Plc in a research note on Thursday, May 11th. Evercore ISI lifted their price target on shares of Icon Plc from $91.50 to $92.00 and gave the company an outperform rating in a research note on Friday, April 28th. Mizuho began coverage on shares of Icon Plc in a research note on Thursday, March 23rd. They issued a neutral rating and a $66.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Icon Plc from a hold rating to a sell rating in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. Icon Plc presently has an average rating of Hold and an average price target of $80.80.

Shares of Icon Plc (NASDAQ ICLR) traded down 0.18% during trading on Wednesday, hitting $93.93. The company’s stock had a trading volume of 164,665 shares. The firm’s 50 day moving average price is $85.18 and its 200-day moving average price is $81.24. The company has a market cap of $5.05 billion, a PE ratio of 19.50 and a beta of 0.63. Icon Plc has a 52 week low of $63.94 and a 52 week high of $94.71.

Icon Plc (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, April 27th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.02. Icon Plc had a net margin of 15.60% and a return on equity of 29.47%. The business had revenue of $432 million for the quarter, compared to analyst estimates of $432.21 million. During the same quarter last year, the firm earned $1.12 EPS. Icon Plc’s quarterly revenue was up 7.9% compared to the same quarter last year. On average, analysts predict that Icon Plc will post $5.17 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the stock. Ladenburg Thalmann Financial Services Inc. increased its stake in Icon Plc by 27.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,460 shares of the medical research company’s stock worth $111,000 after buying an additional 312 shares during the period. Flinton Capital Management LLC acquired a new stake in Icon Plc during the fourth quarter worth about $125,000. US Bancorp DE increased its stake in Icon Plc by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares during the period. Quantbot Technologies LP increased its stake in Icon Plc by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after buying an additional 587 shares during the period. Finally, IFP Advisors Inc increased its stake in Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares during the period. Institutional investors own 88.14% of the company’s stock.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ICLR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment